CD33‐targeting extracellular vesicles deliver antisense oligonucleotides against FLT3‐ITD and miR‐125b for specific treatment of acute myeloid leukaemia
Sign Up to like & getrecommendations! Published in 2022 at "Cell Proliferation"
DOI: 10.1111/cpr.13255
Abstract: Acute Myeloid Leukaemia (AML) is the most common blood cancer in adults. Although 2 out of 3 AML patients go into total remission after chemotherapies and targeted therapies, the disease recurs in 60%–65% of younger… read more here.
Keywords: acute myeloid; cd33 targeting; myeloid leukaemia; extracellular vesicles ... See more keywords
IMGN779, a Novel CD33-Targeting Antibody–Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-17-1077
Abstract: The myeloid differentiation antigen CD33 has long been exploited as a target for antibody-based therapeutic approaches in acute myeloid leukemia (AML). Validation of this strategy was provided with the approval of the CD33-targeting antibody–drug conjugate… read more here.
Keywords: cd33 targeting; cd33; targeting antibody; aml ... See more keywords